The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are d2-selective ex vivo but not in vitro

Neuropsychopharmacology

Volumn 35, Issue 8, 2010, Pages 1826-1835

  McCormick, Patrick N ^a,b   Kapur, Shitij ^b,c   Graff Guerrero, Ariel ^b,c   Raymond, Roger ^c   Nobrega, José N ^a,b,c   Wilson, Alan A ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

3H (+) PHNO; Antipsychotic drugs; Autoradiography; Dopamine D2 receptor; Dopamine D3 receptor; Rat

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NAXAGOLIDE; OLANZAPINE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING SITE; CEREBELLUM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SELECTIVITY; EX VIVO STUDY; GLOBUS PALLIDUS; IN VIVO STUDY; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SUBSTANTIA NIGRA;

ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BENZODIAZEPINES; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HUMANS; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RISPERIDONE; TRITIUM; VITAMIN K 1;

EID: 77953610258     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.50     Document Type: Article

References (45)

1. 3H]PD 128907, a putatively selective ligand for the D3 dopamine receptor, in rat brain: a receptor binding and quantitative autoradiographic study. Neuropsychopharmacology 18: 305-316.
2. Beckstead RM, Domesick VB, Nauta WJ (1979). Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Res 175: 191-217.
3. 18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13: 24-42.
4. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538-544.
5. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR et al (1994). Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther 268: 417-426.
6. Fujita M (2001). In vivo receptor imaging with PET and SPET-pitfalls in quantification. Int Rev Psychiatry 13: 34-39.
7. 11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97: 1089-1103.
8. 11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 27: 857-871.
9. 11C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 21: 1342-1353.
10. 11C]-(+)-PHNO PET by ABT-92. Int J Neuropsychopharmacol 11(Suppl. S1): 223.
11. 11C]-(+)-PHNO. Arch Gen Psychiatry 66: 606-615.
12. 11C]raclopride binding. J Cereb Blood Flow Metab 18: 941-950.
13. Joyce JN, Millan MJ (2005). Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 10: 917-925.
14. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305: 625-631.
15. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000). A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57: 553-559.
16. Kapur S, Zipursky RB, Remington G (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286-293.
17. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL et al (1996). Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 317: 417-423.
18. 11C] raclopride studies. J Cereb Blood Flow Metab 16: 42-52.
19. Landwehrmeyer B, Mengod G, Palacios JM (1993). Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histo-chemistry and ligand binding autoradiography. Eur J Neurosci 5: 145-153.
20. Leopoldo M, Berardi F, Colabufo NA, De Giorgio P, Lacivita E, Perrone R et al (2002). Structure-affinity relationship study on N-[4-(4-arylpiperazin-1- yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands. J Med Chem 45: 5727-5735.
21. Levant B (1998). Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res 800: 269-274.
22. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89: 8155-8159.
23. 11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro. Synapse 63: 998-1009.
24. 3H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nucl Med Biol 35: 11-17.
25. 11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60: 485-495.
26. Newman AH, Grundt P, Nader MA (2005). Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48: 3663-3679.
27. 3H](+)PHNO. Synapse 17: 167-172.
28. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995). D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444-1449.
29. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C et al (1993). Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33: 227.
30. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. Academic Press: New York.
31. Rabiner E, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R et al (2009). In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mince. Synapse 63: 782-793.
32. Schotte A, Janssen PF, Bonaventure P, Leysen JE (1996a). Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Histochem J 28: 791-799.
33. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS et al (1996b). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: 57-73.
34. Schotte A, Janssen PF, Gommeren W, Luyten WH, Leysen JE (1992). Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo. Eur J Pharmacol 218: 373-375.
35. Seabrook GR, Patel S, Marwood R, Emms F, Knowles MR, Freedman SB et al (1992). Stable expression of human D3 dopamine receptors in GH4C1 pituitary cells. FEBS Lett 312: 123-126.
36. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146-151.
37. Swanson LW (1982). The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 9: 321-353.
38. Tang L, Todd RD, Heller A, O'Malley KL (1994). Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther 268: 495-502.
39. 11C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. Synapse 37: 95-103.
40. 11C]MNPA and its response to methamphetamine in the monkey brain. Neuroimage 41: T40.
41. van der Zwaal EM, Luijendijk MC, Adan RA, la Fleur SE (2008). Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol 585: 130-136.
42. van Vliet LA, Rodenhuis N, Dijkstra D, Wikstrom H, Pugsley TA, Serpa KA et al (2000). Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b- tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907). J Med Chem 43: 2871-2882.
43. 11C]-(+)-PHNO. Biol Psychiatry 59: 389-394.
44. 11C]-(+)-4-propyl-3,4,4a,5, 6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48: 4153-4160.
45. Yildiz A, Eryilmaz M, Gungor F, Erkilic M, Karayalcin B (2000). Regional cerebral blood flow in schizophrenia before and after neuroleptic medication. Nucl Med Commun 21: 1113-1118.